These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34013938)

  • 21. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4.
    Wang X; Zhang Y; Peng Y; Hutchinson MR; Rice KC; Yin H; Watkins LR
    Br J Pharmacol; 2016 Mar; 173(5):856-69. PubMed ID: 26603732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the sites of opioid influence on anterior pituitary hormone secretion using a quaternary opiate antagonist.
    Simpkins JW; Swager D; Millard WJ
    Neuroendocrinology; 1991 Oct; 54(4):384-90. PubMed ID: 1661859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
    Walker BM; Koob GF
    Neuropsychopharmacology; 2008 Feb; 33(3):643-52. PubMed ID: 17473837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nalmefene attenuates malignant potential in colorectal cancer cell via inhibition of opioid receptor.
    Wu Q; Chen X; Wang J; Sun P; Weng M; Chen W; Sun Z; Zhu M; Miao C
    Acta Biochim Biophys Sin (Shanghai); 2018 Feb; 50(2):156-163. PubMed ID: 29267844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bordetella pertussis Lipid A Recognition by Toll-like Receptor 4 and MD-2 Is Dependent on Distinct Charged and Uncharged Interfaces.
    Maeshima N; Evans-Atkinson T; Hajjar AM; Fernandez RC
    J Biol Chem; 2015 May; 290(21):13440-53. PubMed ID: 25837248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling.
    Klett J; Reeves J; Oberhauser N; Pérez-Regidor L; Martín-Santamaria S
    Curr Top Med Chem; 2014; 14(23):2672-83. PubMed ID: 25515751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting the chiral recognition of TLR4/MD2 with Neoseptin-3 enantiomers by molecular dynamics simulations.
    Zhang C; Wu S; Li M; Li P; Du X; Wang Y; Wang X
    Phys Chem Chem Phys; 2024 Mar; 26(12):9309-9316. PubMed ID: 38426248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding of a new opiate antagonist, nalmefene, to rat brain membranes.
    Michel ME; Bolger G; Weissman BA
    Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid differentiation protein 2 silencing decreases LPS-induced cytokine production and TLR4/MyD88 pathway activity in alveolar macrophages.
    Ren W; Hu L; Hua F; Jin J; Wang Y; Zhu L
    Immunol Lett; 2011 Dec; 141(1):94-101. PubMed ID: 21849156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
    Wang DS; Sternbach G; Varon J
    J Emerg Med; 1998; 16(3):471-5. PubMed ID: 9610980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure.
    Rose JH; Karkhanis AN; Steiniger-Brach B; Jones SR
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27472317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats.
    Vink R; McIntosh TK; Rhomhanyi R; Faden AI
    J Neurosci; 1990 Nov; 10(11):3524-30. PubMed ID: 2230942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates.
    Simpkins JW; Smulkowski M; Dixon R; Tuttle R
    J Pharmacol Exp Ther; 1988 Jan; 244(1):195-205. PubMed ID: 3335997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats.
    Faden AI; Shirane R; Chang LH; James TL; Lemke M; Weinstein PR
    J Pharmacol Exp Ther; 1990 Nov; 255(2):451-8. PubMed ID: 2243336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys.
    Mello NK; Mendelson JH; Kelly M
    Pharmacol Biochem Behav; 2000 Jun; 66(2):275-83. PubMed ID: 10880679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for ProTα-TLR4/MD-2 binding: molecular dynamics and gravimetric assay studies.
    Omotuyi O; Matsunaga H; Ueda H
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S223-9. PubMed ID: 25604147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progesterone inhibits the estrogen-induced gonadotropin surge in the rhesus monkey independent of endogenous opiates.
    Van Vugt DA; Heisler LE; Reid RL
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1312-9. PubMed ID: 1592876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of nalmefene on energy balance and glucose regulation in Zucker rats.
    McLaughlin CL; Baile CA; Gingerich RL; Michel ME
    Physiol Behav; 1986; 37(6):899-908. PubMed ID: 2947253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.
    Geer EB; Landman RE; Wardlaw SL; Conwell IM; Freda PU
    Pituitary; 2005; 8(2):115-22. PubMed ID: 16379031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.